Arginine silicate inositol complex and use thereof
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-031/70
A61K-031/195
A61K-031/185
출원번호
UP-0146620
(2005-06-06)
등록번호
US-7576132
(2009-08-31)
발명자
/ 주소
Juturu, Vijaya
Komorowski, James R.
출원인 / 주소
Nutrition 21, Inc.
대리인 / 주소
Knobbe Martens Olson & Bear LLP
인용정보
피인용 횟수 :
0인용 특허 :
28
초록▼
A method for preventing and treating a variety of disease states and disorders is provided, comprising the administration of an arginine silicate inositol complex to an individual in the presence of medical therapy or absence of medical therapy. Examples of said disease states and disorders include
A method for preventing and treating a variety of disease states and disorders is provided, comprising the administration of an arginine silicate inositol complex to an individual in the presence of medical therapy or absence of medical therapy. Examples of said disease states and disorders include bone and cartilage disorders and cardiovascular disease and its associated micro and macro vascular complications including infections and inflammation of all these diseases in combination or without. Advantageously, the amount of arginine silicate inositol complex administered per day is between about 2 mg/Kg body weight to 2,500 mg/Kg body weight or from a low dose to a higher dose to observe normal metabolic functions and healthy and the delivery is parenteral, oral or intravenous or topical by solid or liquid or both.
대표청구항▼
What is claimed is: 1. A method of decreasing insulin resistance in an individual, comprising; identifying an individual in need of decreased insulin resistance; and administering to said individual an effective amount of an arginine silicate inositol complex. 2. The method of claim 1, wherein s
What is claimed is: 1. A method of decreasing insulin resistance in an individual, comprising; identifying an individual in need of decreased insulin resistance; and administering to said individual an effective amount of an arginine silicate inositol complex. 2. The method of claim 1, wherein said administering step is parenteral or oral. 3. The method of claim 1, wherein said effective amount of said arginine silicate inositol complex is between about 2 mg/kg body weight and about 2,500 mg/kg body weight. 4. The method of claim 3, wherein said effective amount of said arginine silicate complex is between about 5 mg/kg body weight and about 1,000 mg/kg body weight. 5. The method of claim 1, wherein said individual is a mammal. 6. A method for increasing nitric oxide production in an individual, comprising the step of administering to said individual an effective amount of an arginine silicate inositol complex. 7. The method of claim 6, wherein said administering step is parenteral or oral. 8. The method of claim 6, wherein said effective amount of said arginine silicate complex is between about 2 mg/kg body weight and about 2,500 mg/kg body weight. 9. The method of claim 7, wherein said individual is a mammal. 10. A method for treating a disorder caused by or exacerbated by reduced levels of nitric oxide by increasing concentrations of nitric oxide in an individual, comprising; identifying an individual in need of an increased concentration of nitric oxide; and administering to said individual an effective amount of an arginine silicate inositol complex. 11. The method of claim 10, wherein said disorder is selected from the group consisting of pulmonary hypertension, renal disease, hypertension, diabetes, hypercholesterolemia, hyperglycemia, heart failure, Fabry's disease, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease, Crohn's disease, ulcerative colitis, perinatal asphyxia, meconium aspiration syndrome, Group B strep sepsis, congenital diaphragmatic hernia, isehemic heart disease, hyperhomocysteinemia, multiple sclerosis, Takayasu's arteritis, autosomal dominant polycystie kidney disease, end-stage renal failure, and liver disease. 12. The method of claim 10, wherein said arginine silicate inositol complex is administered parenterally or orally. 13. The method of claim 10, further comprising administering a second beneficial agent effective in treating a disorder caused by or exacerbated by reduced levels of NO, wherein said second beneficial agent is a conventional therapy for NO deficiencies. 14. The method of claim 10, wherein said effective amount of arginine silicate complex is between about 2 mg/kg body weight and about 2,500 mg/kg body weight. 15. The method of claim 10, wherein said individual is a mammal.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (28)
Godfrey John C. (Huntingdon Valley PA), Amino acid flavorings of aluminum astringent for oral use.
Lu Mou-Ying F. (Lake Bluff IL) Reiland Thomas L. (Gages Lake IL), Compositions and methods for the sublingual or buccal administration of therapeutic agents.
Platz Robert M. ; Kimura Shigenobu,JPX ; Satoh Yu-ichiro,JPX ; Foster Linda C., Methods and compositions for the dry powder formulation of interferons.
Levere Richard D. (5 Seymour Pl. W. Armonk NY 10504) Abraham Nader G. (143 Charter Cir. Ossining NY 10562) Schwartzman Michel L. (415 Old Country Rd. Elmsford NY 10523) Martasek Pavel (60 Hillcrest R, Use of L-arginine in the treatment of hypertension and other vascular disorders.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.